Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

May 09, 2025

Indonesia, CRUK Scotland Institute partner to advance cancer research

The Ministry of Health of the Republic of Indonesia and the CRUK Scotland Institute entered into a partnership to advance cancer research, build capacity in cancer care, and support evidence-based health policies.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

University of Oklahoma researchers have discovered one reason why the brain tumor glioblastoma is so aggressive.

May 09, 2025

Vol.51 No.18

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Clinical

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

May 02, 2025

Vol.51 No.17

By Jacquelyn Cobb

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

YOU MAY BE INTERESTED IN

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Indonesia, CRUK Scotland Institute partner to advance cancer research

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

Renew today!

Subscriber content

Never miss an issue!

Login

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

YOU MAY BE INTERESTED IN

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

Indonesia, CRUK Scotland Institute partner to advance cancer research

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child